Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 57

1.

A Single-Center, Open-Label, 3-Way Crossover Trial to Determine the Pharmacokinetic and Pharmacodynamic Interaction Between Nebivolol and Valsartan in Healthy Volunteers at Steady State.

Chen CL, Desai-Krieger D, Ortiz S, Kerolous M, Wright HM, Ghahramani P.

Am J Ther. 2015 Sep-Oct;22(5):e130-40. doi: 10.1097/MJT.0000000000000247.

2.

Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.

Martínez-Salamanca JI, La Fuente JM, Cardoso J, Fernández A, Cuevas P, Wright HM, Angulo J.

J Sex Med. 2014 May;11(5):1182-92.

PMID:
24877179
3.

Investigation of nebivolol as a novel therapeutic agent for the treatment of Alzheimer's disease.

Wang J, Wright HM, Vempati P, Li H, Wangsa J, Dzhuan A, Habbu K, Knable LA, Ho L, Pasinetti GM.

J Alzheimers Dis. 2013;33(4):1147-56. doi: 10.3233/JAD-2012-120904.

PMID:
23128558
4.

Investigation of bendamustine HCL in a phase 2 study in women with resistant ovarian cancer.

Baker AF, Roe DJ, Laughren C, Cohen JL, Wright HM, Clouser MC, Cui H, Alberts DS, Chambers SK.

Invest New Drugs. 2013 Feb;31(1):160-6. doi: 10.1007/s10637-012-9827-5.

5.

Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.

Chambers SK, Chow HH, Janicek MF, Cragun JM, Hatch KD, Cui H, Laughren C, Clouser MC, Cohen JL, Wright HM, Abu Shahin N, Alberts DS.

Clin Cancer Res. 2012 May 1;18(9):2668-78. doi: 10.1158/1078-0432.CCR-12-0261.

6.

Intravenous fat emulsion as treatment for ivermectin toxicosis in three dogs homozygous for the ABCB1-1Δ gene mutation.

Wright HM, Chen AV, Talcott PA, Poppenga RH, Mealey KL.

J Vet Emerg Crit Care (San Antonio). 2011 Dec;21(6):666-72. doi: 10.1111/j.1476-4431.2011.00687.x.

PMID:
22316260
7.

Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation.

Aragón JP, Condit ME, Bhushan S, Predmore BL, Patel SS, Grinsfelder DB, Gundewar S, Jha S, Calvert JW, Barouch LA, Lavu M, Wright HM, Lefer DJ.

J Am Coll Cardiol. 2011 Dec 13;58(25):2683-91. doi: 10.1016/j.jacc.2011.09.033.

8.

Pharmacokinetics of oral rufinamide in dogs.

Wright HM, Chen AV, Martinez SE, Davies NM.

J Vet Pharmacol Ther. 2012 Dec;35(6):529-33. doi: 10.1111/j.1365-2885.2011.01353.x.

PMID:
22132708
9.

High-performance liquid chromatographic analysis of lacosamide in canine serum using ultraviolet detection: application to pre-clinical pharmacokinetics in dogs.

Martinez SE, Bowen KA, Remsberg CM, Takemoto JK, Wright HM, Chen-Allen AV, Davies NM.

Biomed Chromatogr. 2012 May;26(5):606-9. doi: 10.1002/bmc.1704.

PMID:
21898475
10.

Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.

Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Nagle RB, Wright HM, Cohen JL, Alberts DS.

Clin Cancer Res. 2010 Nov 1;16(21):5320-8. doi: 10.1158/1078-0432.CCR-10-0974.

11.

Nebivolol dilates human penile arteries and reverses erectile dysfunction in diabetic rats through enhancement of nitric oxide signaling.

Angulo J, Wright HM, Cuevas P, González-Corrochano R, Fernández A, Cuevas B, La Fuente JM, Gupta S, Sáenz de Tejada I.

J Sex Med. 2010 Aug;7(8):2681-97. doi: 10.1111/j.1743-6109.2010.01710.x.

PMID:
20214719
12.

Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.

Gupta S, Wright HM.

Cardiovasc Ther. 2008 Fall;26(3):189-202. doi: 10.1111/j.1755-5922.2008.00054.x. Review.

PMID:
18786089
13.

Modulation of TRPC5 cation channels by halothane, chloroform and propofol.

Bahnasi YM, Wright HM, Milligan CJ, Dedman AM, Zeng F, Hopkins PM, Bateson AN, Beech DJ.

Br J Pharmacol. 2008 Apr;153(7):1505-12. doi: 10.1038/sj.bjp.0707689.

14.

Structural and functional evolution of transthyretin and transthyretin-like proteins.

Hennebry SC, Wright HM, Likic VA, Richardson SJ.

Proteins. 2006 Sep 1;64(4):1024-45.

PMID:
16783790
15.

Evolution of the thyroid hormone distributor protein transthyretin in microbes, C. elegans, and vertebrates.

Richardson SJ, Hennebry SC, Smith BJ, Wright HM.

Ann N Y Acad Sci. 2005 Apr;1040:448-51.

PMID:
15891085
16.

Identification of resected root-end dentinal cracks: a comparative study of transillumination and dyes.

Wright HM Jr, Loushine RJ, Weller RN, Kimbrough WF, Waller J, Pashley DH.

J Endod. 2004 Oct;30(10):712-5.

PMID:
15448465
17.

Creation and development of an All-Wales Health Library Catalogue.

John J, Wright HM.

Health Info Libr J. 2004 Jun;21 Suppl 1:33-8.

18.

Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation.

Hauser S, Adelmant G, Sarraf P, Wright HM, Mueller E, Spiegelman BM.

J Biol Chem. 2000 Jun 16;275(24):18527-33.

19.

A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation.

Wright HM, Clish CB, Mikami T, Hauser S, Yanagi K, Hiramatsu R, Serhan CN, Spiegelman BM.

J Biol Chem. 2000 Jan 21;275(3):1873-7.

20.

Loss-of-function mutations in PPAR gamma associated with human colon cancer.

Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, Eng C.

Mol Cell. 1999 Jun;3(6):799-804.

Items per page

Supplemental Content

Loading ...
Support Center